Your browser doesn't support javascript.
loading
Behçet syndrome.
Yazici, Yusuf; Hatemi, Gulen; Bodaghi, Bahram; Cheon, Jae Hee; Suzuki, Noburu; Ambrose, Nicola; Yazici, Hasan.
Afiliação
  • Yazici Y; Division of Rheumatology, New York University School of Medicine, New York, NY, USA. yusuf.yazici@nyulangone.org.
  • Hatemi G; Division of Rheumatology, Department of Internal Medicine and Behçet's Disease Research Center, Istanbul University - Cerrahpasa, Istanbul, Turkey.
  • Bodaghi B; Sorbonne University, IHU FOReSIGHT, Pitié-Salpêtrière Hospital UMR 7211 UPMC/CNRS, U972 INSERM, Transimmunom Laboratory of Excellence Sorbonne University, Paris, France.
  • Cheon JH; Department of Internal Medicine, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea.
  • Suzuki N; Department of Immunology and Medicine, St. Marianna University School of Medicine, Miyamae-ku, Kawasaki, Japan.
  • Ambrose N; University College London, London, UK.
  • Yazici H; (Rheumatology) Academic Hospital Istanbul, Istanbul, Turkey.
Nat Rev Dis Primers ; 7(1): 67, 2021 09 16.
Article em En | MEDLINE | ID: mdl-34531393
ABSTRACT
Behçet syndrome is a systemic vasculitis with an unknown aetiology affecting the small and large vessels of the venous and arterial systems. The presence of symptom clusters, regional differences in disease expression and similarities with, for example, Crohn's disease suggest that multiple pathological pathways are involved in Behçet syndrome. These disease features also make formulating disease criteria difficult. Genetic studies have identified HLA-B*51 as a genetic risk factor. However, the low prevalence of HLA-B*51 in many patients with bona fide disease, especially in non-endemic regions, suggests that other factors must also be operative in Behçet syndrome. Despite lacking a clear aetiological mechanism and definition, management of manifestations that include major vascular disease, eye disease and central nervous system involvement has improved with the help of new technology. Furthermore, even with our incomplete understanding of disease mechanisms, the prognoses of patients with Behçet syndrome, including those with eye disease, continue to improve. New treatment options and a better understanding of the underlying pathogenesis for various manifestations of this condition are required to further improve the management of the disease, which will improve patient quality of life.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome de Behçet Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome de Behçet Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article